About
About Vcanbio Cell & Gene Engineering Corp., Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, children and adults, disease inheritance, and disease susceptibility; and in vitro diagnostic raw materials such as monoclonal antibodies and polyclonal antibody products, and the research, development, production and sales of Class I, Class II and Class III in vitro diagnostic reagents and medical devices. In addition, it is involved in the research, development, production, and sales of biological genes, proteins, antibodies, and pharmaceutical intermediates. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.
Visit company website
5 years, 5 months ago
Vcanbio Cell & Gene Engineering Corp., Ltd is currently in a long term uptrend where the price is trading 5.7% above its 200 day moving average.
From a valuation standpoint, the stock is 31.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.6.
Vcanbio Cell & Gene Engineering Corp., Ltd's total revenue rose by 3.8% to $350M since the same quarter in the previous year.
Its net income has increased by 70.5% to $52M since the same quarter in the previous year.
Finally, its free cash flow fell by 17.0% to $45M since the same quarter in the previous year.
Based on the above factors, Vcanbio Cell & Gene Engineering Corp., Ltd gets an overall score of 4/5.